BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 23358982)

  • 1. Activating germline R776H mutation in the epidermal growth factor receptor associated with lung cancer with squamous differentiation.
    van Noesel J; van der Ven WH; van Os TA; Kunst PW; Weegenaar J; Reinten RJ; Kancha RK; Duyster J; van Noesel CJ
    J Clin Oncol; 2013 Apr; 31(10):e161-4. PubMed ID: 23358982
    [No Abstract]   [Full Text] [Related]  

  • 2. Transformation to a squamous cell carcinoma phenotype of an EGFR-mutated NSCLC patient after treatment with an EGFR-tyrosine kinase inhibitor.
    Kuiper JL; Ronden MI; Becker A; Heideman DA; van Hengel P; Ylstra B; Thunnissen E; Smit EF
    J Clin Pathol; 2015 Apr; 68(4):320-1. PubMed ID: 25661795
    [No Abstract]   [Full Text] [Related]  

  • 3. Gefitinib-sensitive mutations of the epidermal growth factor receptor tyrosine kinase domain in chinese patients with non-small cell lung cancer.
    Mu XL; Li LY; Zhang XT; Wang MZ; Feng RE; Cui QC; Zhou HS; Guo BQ
    Clin Cancer Res; 2005 Jun; 11(12):4289-94. PubMed ID: 15958609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term gefitinib treatment of occult lung carcinoma with multiple brain metastases.
    Kobayashi T; Takeda M; Marumo S; Koshimo Y; Teranishi T; Higami Y; Kato M
    Lung Cancer; 2013 Apr; 80(1):109-11. PubMed ID: 23279871
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased epidermal growth factor receptor (EGFR) gene copy number is strongly associated with EGFR mutations and adenocarcinoma in non-small cell lung cancers: a chromogenic in situ hybridization study of 182 patients.
    Chang JW; Liu HP; Hsieh MH; Fang YF; Hsieh MS; Hsieh JJ; Chiu YT; Tsai HY; Chen YH; Chen YT; Hsu HY; Chen YT; Tsai SF; Chen YR; Hsi BL; Huang SF
    Lung Cancer; 2008 Sep; 61(3):328-39. PubMed ID: 18304690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High frequency of epidermal growth factor receptor mutations with complex patterns in non-small cell lung cancers related to gefitinib responsiveness in Taiwan.
    Huang SF; Liu HP; Li LH; Ku YC; Fu YN; Tsai HY; Chen YT; Lin YF; Chang WC; Kuo HP; Wu YC; Chen YR; Tsai SF
    Clin Cancer Res; 2004 Dec; 10(24):8195-203. PubMed ID: 15623594
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2011 Mar; 25(6):1-5. PubMed ID: 21638942
    [No Abstract]   [Full Text] [Related]  

  • 8. Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese.
    Uramoto H; Sugio K; Oyama T; Ono K; Sugaya M; Yoshimatsu T; Hanagiri T; Morita M; Yasumoto K
    Lung Cancer; 2006 Jan; 51(1):71-7. PubMed ID: 16198442
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erlotinib in lung cancer - molecular and clinical predictors of outcome.
    Tsao MS; Sakurada A; Cutz JC; Zhu CQ; Kamel-Reid S; Squire J; Lorimer I; Zhang T; Liu N; Daneshmand M; Marrano P; da Cunha Santos G; Lagarde A; Richardson F; Seymour L; Whitehead M; Ding K; Pater J; Shepherd FA
    N Engl J Med; 2005 Jul; 353(2):133-44. PubMed ID: 16014883
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EGFR mutation conferring primary resistance to gefitinib in non-small-cell lung cancer.
    Shih JY; Gow CH; Yang PC
    N Engl J Med; 2005 Jul; 353(2):207-8. PubMed ID: 16014893
    [No Abstract]   [Full Text] [Related]  

  • 11. First-line treatment for advanced nonsmall cell lung cancer harboring activating epidermal growth factor receptor mutation: epidermal growth factor receptor tyrosine kinase inhibitors or chemotherapy?
    Gridelli C
    Curr Opin Oncol; 2011 Mar; 23(2):131-2. PubMed ID: 21307676
    [No Abstract]   [Full Text] [Related]  

  • 12. Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
    Pao W; Miller VA
    J Clin Oncol; 2005 Apr; 23(11):2556-68. PubMed ID: 15767641
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Relevance of epidermal growth factor receptor genomic gain in predicting clinical response to kinase inhibitors in non-small-cell lung cancer.
    Reddy GK
    Clin Lung Cancer; 2005 Nov; 7(3):163-5. PubMed ID: 16354309
    [No Abstract]   [Full Text] [Related]  

  • 14. Familial lung adenocarcinoma caused by the EGFR V843I germ-line mutation.
    Ohtsuka K; Ohnishi H; Kurai D; Matsushima S; Morishita Y; Shinonaga M; Goto H; Watanabe T
    J Clin Oncol; 2011 Mar; 29(8):e191-2. PubMed ID: 21172876
    [No Abstract]   [Full Text] [Related]  

  • 15. Intron 1 CA dinucleotide repeat polymorphism and mutations of epidermal growth factor receptor and gefitinib responsiveness in non-small-cell lung cancer.
    Han SW; Jeon YK; Lee KH; Keam B; Hwang PG; Oh DY; Lee SH; Kim DW; Im SA; Chung DH; Heo DS; Bang YJ; Kim TY
    Pharmacogenet Genomics; 2007 May; 17(5):313-9. PubMed ID: 17429313
    [TBL] [Abstract][Full Text] [Related]  

  • 16. EGFR mutations and molecularly targeted therapy: a new era in the treatment of lung cancer.
    Dowell JE; Minna JD
    Nat Clin Pract Oncol; 2006 Apr; 3(4):170-1. PubMed ID: 16596125
    [No Abstract]   [Full Text] [Related]  

  • 17. Screening for epidermal growth factor receptor mutations in lung cancer.
    Rosell R; Moran T; Queralt C; Porta R; Cardenal F; Camps C; Majem M; Lopez-Vivanco G; Isla D; Provencio M; Insa A; Massuti B; Gonzalez-Larriba JL; Paz-Ares L; Bover I; Garcia-Campelo R; Moreno MA; Catot S; Rolfo C; Reguart N; Palmero R; Sánchez JM; Bastus R; Mayo C; Bertran-Alamillo J; Molina MA; Sanchez JJ; Taron M;
    N Engl J Med; 2009 Sep; 361(10):958-67. PubMed ID: 19692684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Epidermal growth factor receptor mutations and tyrosine kinase inhibitor therapy in advanced non-small-cell lung cancer.
    Technol Eval Cent Assess Program Exec Summ; 2007 Nov; 22(6):1-3. PubMed ID: 18080406
    [No Abstract]   [Full Text] [Related]  

  • 19. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.
    Bell DW; Gore I; Okimoto RA; Godin-Heymann N; Sordella R; Mulloy R; Sharma SV; Brannigan BW; Mohapatra G; Settleman J; Haber DA
    Nat Genet; 2005 Dec; 37(12):1315-6. PubMed ID: 16258541
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Good clinical response to gefitinib in a non-small cell lung cancer patient harboring a rare somatic epidermal growth factor gene point mutation; codon 768 AGC > ATC in exon 20 (S768I).
    Masago K; Fujita S; Irisa K; Kim YH; Ichikawa M; Mio T; Mishima M
    Jpn J Clin Oncol; 2010 Nov; 40(11):1105-9. PubMed ID: 20522446
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.